Zydus Lifesciences Limited — Updates, 26-02-2025: Press Release

Zydus Lifesciences is set to launch VaxiFlu-4, India’s first quadrivalent inactivated influenza vaccine for the 2025 southern hemisphere season. This vaccine provides protection against four strains, including two influenza A and two B viruses, aligning with WHO recommendations. Backed by the Central Drug Laboratory, VaxiFlu-4 highlights Zydus’s commitment to public health by improving access to affordable vaccines. Dr. Sharvil Patel, Managing Director, emphasized the significance of preventives in healthcare, particularly as influenza poses a significant public health challenge, with the WHO noting seasonal flu leads to 290,000-650,000 deaths annually. The Vaccine Technology Centre in Ahmedabad, renowned for its vaccine development, produced VaxiFlu-4, reinforcing Zydus's position in the global lifesciences sector. Investors should monitor this initiative closely as it underscores potential growth in the healthcare market and contributes positively to public health solutions.